JP2014517050A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517050A5
JP2014517050A5 JP2014516318A JP2014516318A JP2014517050A5 JP 2014517050 A5 JP2014517050 A5 JP 2014517050A5 JP 2014516318 A JP2014516318 A JP 2014516318A JP 2014516318 A JP2014516318 A JP 2014516318A JP 2014517050 A5 JP2014517050 A5 JP 2014517050A5
Authority
JP
Japan
Prior art keywords
week
compound
dose
disorder
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014516318A
Other languages
English (en)
Japanese (ja)
Other versions
JP6140151B2 (ja
JP2014517050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/061779 external-priority patent/WO2012175531A1/en
Publication of JP2014517050A publication Critical patent/JP2014517050A/ja
Publication of JP2014517050A5 publication Critical patent/JP2014517050A5/ja
Application granted granted Critical
Publication of JP6140151B2 publication Critical patent/JP6140151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014516318A 2011-06-20 2012-06-20 統合失調症の処置において4−((1r,3s)−6−クロロ−3−フェニル−インダン−1−イル)−1,2,2−トリメチル−ピペラジンおよびその塩を投与する方法 Active JP6140151B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161498653P 2011-06-20 2011-06-20
DKPA201100465 2011-06-20
US61/498,653 2011-06-20
DKPA201100465 2011-06-20
PCT/EP2012/061779 WO2012175531A1 (en) 2011-06-20 2012-06-20 Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia

Publications (3)

Publication Number Publication Date
JP2014517050A JP2014517050A (ja) 2014-07-17
JP2014517050A5 true JP2014517050A5 (https=) 2016-11-17
JP6140151B2 JP6140151B2 (ja) 2017-05-31

Family

ID=58794324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516318A Active JP6140151B2 (ja) 2011-06-20 2012-06-20 統合失調症の処置において4−((1r,3s)−6−クロロ−3−フェニル−インダン−1−イル)−1,2,2−トリメチル−ピペラジンおよびその塩を投与する方法

Country Status (23)

Country Link
US (1) US9610287B2 (https=)
EP (1) EP2720698B1 (https=)
JP (1) JP6140151B2 (https=)
KR (1) KR101900989B1 (https=)
CN (1) CN103608015A (https=)
AU (1) AU2012274150B2 (https=)
BR (1) BR112013032178A2 (https=)
CA (1) CA2838055C (https=)
DK (1) DK2720698T3 (https=)
ES (1) ES2694298T3 (https=)
HR (1) HRP20181684T1 (https=)
IL (1) IL230060A (https=)
JO (1) JO3421B1 (https=)
LT (1) LT2720698T (https=)
MX (1) MX349754B (https=)
PL (1) PL2720698T3 (https=)
RS (1) RS57944B1 (https=)
RU (1) RU2613177C2 (https=)
SI (1) SI2720698T1 (https=)
SM (1) SMT201800567T1 (https=)
TW (1) TWI552751B (https=)
WO (1) WO2012175531A1 (https=)
ZA (1) ZA201309617B (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
AU1919901A (en) 1999-11-17 2001-05-30 Luc Adam Pathogen tolerance genes
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
WO2002015675A1 (en) 2000-08-22 2002-02-28 Mendel Biotechnology, Inc. Genes for modifying plant traits iv
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
EP2293067B1 (en) 2001-06-26 2016-04-20 Senomyx, Inc. T1R hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005016232A2 (en) 2002-08-01 2005-02-24 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP3249046B1 (en) 2002-09-18 2020-07-08 Mendel Biotechnology, Inc. Polynucleotides and polypeptides in plants
CA2526274C (en) 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
AU2005229015C1 (en) 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
EP2153848A3 (en) 2005-01-27 2010-07-21 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
KR101338533B1 (ko) 2005-07-19 2013-12-12 스템젠 에스.피.에이. Lif 및 bmp에 의한 종양 줄기 세포의 종양발생가능성의 억제
EP3312194A1 (en) 2005-10-20 2018-04-25 Senomyx, Inc. Cell lines expressing chimeric human sweet-umami and umami-sweet taste receptors
NZ568762A (en) 2005-11-07 2011-11-25 Scripps Research Inst Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードrna転写物
WO2007109347A2 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and ly6 e: targets for cancer diagnosis and therapy
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2061900A2 (en) 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
PT2062049E (pt) 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
WO2008127314A1 (en) 2006-11-22 2008-10-23 President And Fellows Of Harvard College High-sensitivity nanoscale wire sensors
EP2581081A3 (en) 2007-06-01 2013-07-31 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
EP2522754B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
EP2195656A4 (en) 2007-08-21 2011-10-19 Senomyx Inc HUMAN T2R BITTERITY RECEPTORS AND USES THEREOF
CN102099055A (zh) 2007-10-04 2011-06-15 津莫吉尼蒂克斯公司 B7家族成员zB7H6及相关的组合物和方法
EP2212693B1 (en) 2007-10-22 2015-04-22 The Regents of The University of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
EP2219671A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
MX2010010165A (es) 2008-03-17 2010-11-25 Scripps Research Inst Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas.
CN102083850B (zh) 2008-04-21 2015-08-12 加利福尼亚大学董事会 选择性高亲和力多齿配体及其制备方法
JP2011529708A (ja) 2008-08-04 2011-12-15 ユニバーシティ オブ マイアミ 自然免疫応答の調節因子sting(インターフェロン遺伝子の刺激因子)
CN102224254A (zh) 2008-09-23 2011-10-19 哈佛大学校长及研究员协会 Sirt4及其用途
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
EP3623374B1 (en) 2008-12-03 2021-09-08 The Scripps Research Institute Stem cell cultures
WO2010077955A1 (en) 2008-12-17 2010-07-08 The Scripps Research Institute Generation and maintenance of stem cells
WO2010126670A2 (en) 2009-03-27 2010-11-04 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
EP2456460A4 (en) 2009-07-24 2013-02-20 Univ California METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN
CN105911275B (zh) 2009-08-14 2018-06-29 加利福尼亚大学董事会 诊断自闭症的试剂盒
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011038228A1 (en) 2009-09-24 2011-03-31 President And Fellows Of Harvard College Bent nanowires and related probing of species
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
WO2013138456A1 (en) 2012-03-14 2013-09-19 University Of Central Florida Research Foundation, Inc. Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
AU2013252909B2 (en) 2012-04-24 2017-09-28 University Of Miami Perforin 2 defense against invasive and multidrug resistant pathogens
EP3184121A3 (en) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
DK2954323T3 (da) 2013-02-07 2020-07-20 Univ California Anvendelse af translationsprofilering til identifikation af målmolekyler til terapeutisk behandling
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
WO2015089338A2 (en) 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
WO2016195982A2 (en) 2015-06-01 2016-12-08 The Penn State Research Foundation Hepatitis b virus capsid assembly
US10782304B2 (en) 2015-06-24 2020-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for detecting protein-protein interactions
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
KR20190095355A (ko) 2016-12-15 2019-08-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암의 치료를 위한 조성물 및 방법
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
US12016902B2 (en) 2017-04-04 2024-06-25 Loma Linda University Biologic for the treatment of cancer
WO2019207587A1 (en) 2018-04-26 2019-10-31 Technion Research & Development Foundation Limited A device and a method for determining cell indentation activity
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
US20240301510A1 (en) 2020-11-19 2024-09-12 The Chinese University Of Hong Kong Assessing risk for colorectal adenoma recurrence by noninvasive means
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
US20250092106A1 (en) 2022-01-25 2025-03-20 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2024197185A1 (en) 2023-03-21 2024-09-26 The Broad Institute, Inc. Methods and compositions for dissecting organelle physiology

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
PL1658277T3 (pl) 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
AU2006269927B2 (en) 2004-01-12 2013-05-16 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
AU2005235422B2 (en) 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
CN102065861B (zh) * 2008-05-07 2013-10-16 H.隆德贝克有限公司 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪用于改善认知的用途
CN102170884A (zh) * 2008-10-03 2011-08-31 H.隆德贝克有限公司 口服制剂
MX2012000061A (es) 2009-06-24 2012-06-01 Msd Oss Bv Formulaciones inyectables que contienen asenapina, y metodo de tratamiento usando las mismas.

Similar Documents

Publication Publication Date Title
JP2014517050A5 (https=)
RU2014101482A (ru) Способ применения 4-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-1,2,2-триметилпиперазина и его солей в лечении шизофрении
EP3240538B1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP3060200B1 (en) Tyrosine derivatives and compositions comprising them
US20060199805A1 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
JP2021073258A (ja) トラジピタントによる治療方法
JP2015512406A5 (https=)
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
JP2014502641A5 (https=)
JP2021080276A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2015524444A5 (https=)
JP2011520981A5 (https=)
ES2822562T3 (es) Composiciones intranasales para el tratamiento de enfermedades y trastornos neurológicos y degenerativos
JP2016505050A5 (https=)
JP2013536206A5 (https=)
JP2019507786A5 (https=)
TW201211021A (en) Methods of use of cyclic amide derivatives to treat schizophrenia
JP2012502105A5 (https=)
CN115607545B (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
EP3570841A1 (en) PPARy AGONIST FOR THE TREATMENT OF HUNTINGTON'S DISEASE
JP6420923B1 (ja) 医薬
JP2014037445A (ja) 抵抗性統合失調症およびその他のcns疾患の治療
JP2009501205A (ja) 精神病治療用組成物
Huynh et al. Therapies under investigation for treating Parkinson's disease psychosis
TW202539621A (zh) 用於治療巴金森氏症的治療劑